]>
IRCT20171030037093N16 IRCT 2019-07-14 Vice chancellor for research, Shahrekord University of Medical Sciences The evaluation of the effect of cinnarizine and betahistine in the treatment of peripheral vertigo ‏ Comparison of cinnarizine and betahistine in the treatment of peripheral vertigo 2019-07-23 anticipated 170 Complete https://irct.ir/trial/40481 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: The drugs are given without any code tags, and the patient selects one of the two randomly by choosing the code, Blinding description: The drugs are given without any code tags and the patient selects one of two drugs randomly by choosing the code, and the name of each person and the prescription drug code is recorded by the secretary and the patient is not informed about the type of medication. 3 peripheral vertigo. Intervention 1: Intervention group: The first group receives 8 mg of betahistine three times a day. Intervention 2: Intervention group: The second group received 25 mg of cinnarizine three times a day. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I will decide until finishing the study
public Mohammadhosein Saffari
Shariati Blvd., Imam Ali Clinic
Shahrekord Iran (Islamic Republic of) 8816788640 +98 38 3224 2696 Dr.safari@gmail.com Shahre-kord University of Medical Sciences scientific Mohammadhosein Saffari
Shariati Blvd., Imam Ali Clinic
Shahrekord Iran (Islamic Republic of) 8816788640 +98 38 3224 2696 Dr.safari@gmail.com Shahre-kord University of Medical Sciences Iran (Islamic Republic of) Age 18-65 years old Having symptoms of vertigo for at least two months Non-sensitivity to cinnarizine and betahistine Natural Signs and Natural Nerve Findings Failure to receive vertigo control drugs at least 7 days before There is no evidence of the causes of central vertigo in a CT scan performed by a patient before the start of the study 18 years 65 years Both Patients with abnormal vital signs, kidney failure, liver disease, heart disease, active stomach ulcer disease or diabetes Patients with ulcerative diagnosis of vertigo with central causes Brain traumatic brain injury Concomitant use of hypertension drugs such as thiazide, antihistamines, corticosteroids and calcium channel antagonists. Patients who are being treated for benzodiazepines for any reason Patients who have received anti-vertigo during the last week The sensitivity of the drug to cinnarizine and betahistine Those who are pregnant or breastfeeding People who are not satisfied with the study H81.3 Other peripheral vertigo Treatment - Drugs Treatment - Drugs Intervention group: The first group receives 8 mg of betahistine three times a day Intervention group: The second group received 25 mg of cinnarizine three times a day. Number of vertigo attacks. Timepoint: Patients will be asked one week after the start of the study and 8 weeks after the start of the study. Method of measurement: vertigo symptom scale questionnaire. Vice chancellor for research, Shahrekord University of Medical Sciences Approved 2018-07-22 Ethics Committee of Shahrekord University of Medical Sciences Vice chancellor for research, Building No. 2, University headquarters, Ayatollah Kashani Blvd Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)